Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
Open Access
- 21 February 2026
- journal article
- review article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70102
Abstract
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have demonstrated promising effects in promoting weight loss and improving metabolic markers. However, their effectiveness post‐bariatric surgery remains uncertain. Methods: PubMed, Cochrane CENTRAL, and Scopus were queried through March 2025 for randomised controlled trials comparing GLP‐1RA to placebo in post‐bariatric surgery patients. Outcomes included weight loss, BMI, total cholesterol, triglycerides, fasting blood glucose, blood pressure, HbA1c, and adverse events. Random‐effects models were used to calculate standardised mean differences (SMDs), weighted mean differences (WMDs), and risk ratios (RRs). Results: Six trials ( n = 401) were included. GLP‐1RA significantly reduced weight (SMD: −5.96 kg [95% CI: −9.40, −2.53]; p = 0.0007), BMI (WMD: −3.08 kg/m 2 [95% CI: −4.16, −2.00]; p < 0.00001), total cholesterol (WMD: −0.30 mmol/L / −11.60 mg/dL [95% CI: −0.50, −0.09 / −19.34, −3.48]; p = 0.005), and HbA1c (WMD: −0.39% [95% CI: −0.62, −0.17]; p = 0.0007). Total adverse events (RR: 1.49 [95% CI: 1.14, 1.94]; p = 0.003) and nausea (RR: 2.23 [95% CI: 1.21, 4.09]; p = 0.010) were more common with GLP‐1RA compared to placebo. No significant changes were found in blood pressure, triglycerides, or fasting blood glucose. Conclusions: GLP‐1RAs significantly reduce weight, BMI, HbA1c, and total cholesterol in patients following bariatric surgery. These findings highlight the potential of GLP‐1RA therapy post‐bariatric surgery. Future research is warranted to assess the long‐term effects of GLP‐1RA on the post‐operative metabolic profile.Keywords
This publication has 43 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte AxisDrugs, 2017
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From ApoptosisMolecular Endocrinology, 2015
- Adverse Effects of GLP-1 Receptor AgonistsThe Review of Diabetic Studies, 2014
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNSJournal of Endocrinology, 2013
- Refractory and new-onset diabetes more than 5 years after gastric bypass for morbid obesitySurgical Endoscopy, 2012
- GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food IntakeEndocrinology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationBMJ, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003